References:​
(1) Palbace (Palbociclib) prescribing document, Pfizer Products India private Limited, version 6.0 LPDPAB102021.
(2) Rugo H, et al. NPJ Breast Cancer (2022) 8:114.​
(3) DeMichele A, et al. Breast Cancer Res. 2021;23:37. ​
(4) Mycock K,et. al.Curr. Oncol. 2021, 28, 678–688.​
(5) Mycock K,et al. Future Oncol. (2022) 18(3),349–362.​
(6)Richardson D,et al. Breast Cancer ResTrea.2021,187,_113–124.​
(7) De Laurentiis,et al. SABCS 2019;Poster P3-11-25. ​
(8)Karuturi M,et al. SABCS 2020;Poster PS-7-19. ​
(9)Rocque G, et al. ESMO 2022;Poster 266P. ​
(10) Taylor-Stokes G, et al. The Breast 43 (2019) 22-27.
​(11) Waller J,et al. J of Global Oncol 2019.
(12) McCain J. P T. 2015;40(8):511-520.​
(13) Finn RS, et al. ASCO 2022; oral presentation LBA1003. ​
(14) Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729. ​
(15)Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439. ​
(16)Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.​
(17) Pfizer Data on File July 2019. Prescribers, Patients. ​
(18)FDA Approved drugs. IBRANCE. https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance. Accessed March 2023. ​
(19)Pfizer Data on File November 2020. Countries.

​
​